NW
DGX icon

NewEdge Wealth’s Quest Diagnostics DGX Stock Holding History

NewEdge Wealth’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,601
Closed -$451K – 1162
2025
Q4 		$451K Buy
+2,601
New +$474K 0.01% 884
2025
Q3 		– Sell
-1,562
Closed -$272K – 1032
2025
Q2 		$272K Buy
+1,562
New +$271K ﹤0.01% 858

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

NewEdge Wealth's DGX Position: Q1 2026 in Review

NewEdge Wealth sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,601 shares — an estimated $451K sold.

NewEdge Wealth first reported a position in DGX in Q2 2025 and held it in 2 quarters. The position peaked at $451K in Q4 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • NewEdge Wealth reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • NewEdge Wealth sold 2,601 Quest Diagnostics shares in Q1 2026, an estimated $451K.
  • NewEdge Wealth first reported a position in Quest Diagnostics in Q2 2025 and held it in 2 quarters.
  • NewEdge Wealth's Quest Diagnostics position peaked at $451K in Q4 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.